Developer docs
API playgroundTry for free, no card

Search company profiles

BioAscent

Full company profile

uuid0003vmc

Namestring
BioAscent
Legal namestring
BioAscent Discovery Ltd
Websiteurl
bioascent.com
Company typeenum
Private
Founded yearint
2013
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersNewhouse, United Kingdom
HQ citystring
Newhouse
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
drug discovery services, compound management, contract research organization, medicinal chemistry, high-throughput screening
Industry2 codes
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Research and Development in the Physical, Engineering, and Life Sciences54171
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Drug Discovery Contract Research Services
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Integrated Drug Discovery Services
TypeProfessional Services
Description

Full-service CRO offering integrated drug discovery projects covering assay development, screening, medicinal chemistry, synthetic chemistry, computational chemistry, and DMPK services. Provides both standalone and fully integrated project delivery.

bioascent.com
2Compound Management Services
TypeProfessional Services
Description

Compound aggregation, storage, weighing, dissolution, plating (including acoustic dispensing), LC-MS analysis, and distribution services. Operating since 2005 with €20 million facility. Cost-effective, transparent activity-based pricing model.

bioascent.com
3Custom Library Sourcing
TypeTransaction Fee
Description

Rapid selection and sourcing of custom libraries through established partnerships with compound suppliers and aggregators such as MolPort.

bioascent.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Pricing details2 tiers
1Activity-based pricing for compound management services
ModelOtherBilling cadencePay-as-you-go
Notes

Transparent activity-based pricing makes it easy to calculate cost savings. Specific pricing available upon quote request.

bioascent.com
2Integrated drug discovery project pricing
ModelProfessional services/ project-basedBilling cadenceMulti-year contract
Notes

Project-based pricing for integrated drug discovery services. Standalone services available on fee-for-service basis.

bioascent.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

BioAscent is a contract research organization (CRO) providing science-led integrated drug discovery services, including de novo assay development, medicinal and synthetic chemistry, computational chemistry, in vitro biosciences, DMPK, and access to in-house diversity and fragment libraries. It also offers parallel compound management services covering sourcing, secure storage, cherry-picking, plating, and global shipping of chemical libraries, supported by a proprietary web-based inventory platform (Compound Connect) for CRO network coordination.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 81% compound annualised growth over two years
+5 more records
Product overview1 text field

BioAscent offers integrated drug discovery services as a unified platform combining multiple specialized capabilities. The core Integrated Drug Discovery Services platform encompasses Discovery Biology (biochemical/biophysical/cellular assays), In Silico Discovery (computational chemistry and AI), Medicinal Chemistry, Protein Science and Structural Biology, and access to proprietary compound libraries (diversity, fragment, and chemogenomic). Compound Management operates as a parallel core service line providing secure compound storage, cherry picking, plating, and logistics via the proprietary Compound Connect web platform. The services are designed to work together seamlessly on a single site, enabling rapid turnaround from synthesis to screening data for customers ranging from virtual biotechs to big pharma.

Product and service10 records
1Integrated Drug Discovery Services
CategoryDrug Discovery Services
Description

Comprehensive integrated drug discovery offering combining de novo assay development, target analysis, bespoke screening strategies, compound screening (including HTS), medicinal and synthetic chemistry, computational chemistry, DMPK, and in-house diversity and fragment libraries for biotech, pharma, and academic customers.

2Compound Management
CategoryCompound Management Services
Description

Big-pharma calibre compound management services including rapid compound sourcing, secure storage, flexible cherry picking, plating (including acoustic dispensing), LC-MS analysis, and global shipping and logistics, supported by a proprietary web-based inventory platform (Compound Connect).

3Compound Connect
CategoryCompound Management Platform
Description

Proprietary web-based inventory and ordering system providing secure customer access to a customized online compound library, with a fully auditable order fulfilment system interfacing with Titian Mosaic compound management software.

4Medicinal Chemistry Services
CategoryDrug Discovery Services
Description

Proven medicinal and synthetic chemistry expertise supporting drug design, hit-to-lead and lead optimisation campaigns for external pharma and biotech customers.

5In Silico Discovery and Data Analysis
CategoryDrug Discovery Services
Description

Computational chemistry and AI-driven drug discovery services including virtual screening, library design, cheminformatics, molecular dynamics simulations, and generative chemistry for accelerated compound design.

6Discovery Biology Services
CategoryBiology Services
Description

Biochemical, biophysical, and cellular assay development with screening expertise across target classes including GPCRs, kinases, ion channels, and mitochondrial targets.

7Protein Science and Structural Biology
CategoryDrug Discovery Services
Description

Protein production, Surface Plasmon Resonance (SPR) biophysics, and structural biology services including X-ray crystallography and NMR for target-ligand interaction characterisation.

8In-house Diversity, Fragment and Chemogenomic Libraries
CategoryCompound Libraries
Description

Proprietary compound libraries including diversity, fragment, and chemogenomic collections for high-throughput screening campaigns.

9Screening and Characterization Services
CategoryBiology Services
Description

High-throughput screening (HTS) capabilities including functional screening, cell-based phenotypic screening, and whole-organism screening for hit identification.

10Physicochemical Profiling and DMPK
CategoryDrug Discovery Services
Description

Drug metabolism and pharmacokinetics (DMPK) profiling including physicochemical property characterisation and ADMETox prediction services.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-30
Description

Successful collaboration on GPR84 antagonist programme with publication of results. Collaboration between BioAscent researchers and University of Glasgow on GPR84 antagonist drug discovery programme.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-02-26
Description

Research collaboration to profile Chemogenomics Library using VivoScan™ whole-organism screening platform, combining Magnitude's expertise in whole-organism screening with BioAscent's compound management capabilities.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-19
Description

Partnership to fund two PhD studentships supported by Medical Research Scotland, focusing on cancer and metabolic disease research. Project aims to develop new therapeutic approaches for energy metabolism in cancer and predictive models for insulin resistance, leveraging BioAscent's drug discovery capabilities.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-11-19
Description

Strategic collaboration to expand peptide discovery capabilities for GPCR targets. Partnership involves integration of Keltic's PEPSMOL© platform into BioAscent's drug discovery services, aiming to accelerate drug development across multiple therapeutic areas.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-06-19
Description

Collaboration on high-throughput screen (HTS) to identify novel allosteric compounds targeting HSD17β13 enzyme. BioAscent provided assay development and screening services; co-publication on Particle Swarm Optimisation technique published in Cell Press Patterns.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Compound management services for European Lead Factory collections from major pharmaceutical partners including AstraZeneca, Bayer, Grunenthal, Janssen, Merck KgaA, Sanofi, Servier, and UCB.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Academic collaboration with postdoctoral researcher Joan Clark-Nicolas on AI-driven design of novel GLP-1R PAMs using REINVENT4 deep generative reinforcement learning framework.

8University of Edinburgh
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Academic collaboration with PhD student Ryan Zhu on generative AI for NLRP3 inflammasome inhibitor design using REINVENT4 framework.

bioascent.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Summer internship collaboration with MSc student Donaldson Chuks Okolo on applying machine learning to predict buffer effects on assay performance using Bayesian optimisation.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration on screening and characterisation of mitochondria gatekeeper protein inhibitors using Seahorse XF Pro Platform.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

China-headquartered global CRO/CDMO with end-to-end small molecule discovery, biology and DMPK capabilities. Sets the global price/throughput benchmark for integrated discovery work that BioAscent competes against for biotech and pharma R&D budgets.

TypeBroad incumbent
Description

China-founded, globally integrated CRO/CDMO with chemistry, biology, DMPK and safety services. Competes for the same pharma/biotech integrated discovery contracts, particularly on price-sensitive programmes where scale matters.

TypeBroad incumbent
Description

Global CRO with substantial early-stage discovery, safety assessment and manufacturing services. Competes with BioAscent in integrated discovery and adjacent services, but at far greater scale and across a much broader portfolio.

TypeDirect peer
Description

China-based DNA-encoded library and small molecule discovery CRO. Highly comparable in screening library and early discovery specialisation, and increasingly competes for biotech customers seeking library-driven hit identification services globally.

TypeRegional player
Description

Poland-based integrated drug discovery CRO with medicinal chemistry, in vitro biology and DMPK. Comparable in service mix and emerging-stage positioning; competes mainly in Central/Eastern Europe rather than the UK-centric footprint of BioAscent.

TypeDirect peer
Description

UK-based integrated drug discovery CRO with medicinal chemistry, biology and DMPK services. Closely comparable in scale and service offering, competing head-to-head with BioAscent for UK and European biotech discovery outsourcing.

TypeBroad incumbent
Description

Large Hamburg-based drug discovery CRO with end-to-end platforms across modalities including small molecules, biologics and cell therapy. Comparable integrated discovery offering but at much greater scale and broader modality coverage than BioAscent.

TypeDirect peer
Description

UK-headquartered CRO (formed from Peakdale Molecular and other acquisitions) offering chemistry, biology and DMPK services. Comparable UK-based discovery CRO with overlapping customer base in European biotech and pharma.

TypeBroad incumbent
Description

Discovery arm of Eurofins Scientific offering in vitro pharmacology, ADME and integrated discovery services. Overlaps with BioAscent's biology and DMPK capabilities and competes for European biotech outsourcing budgets at greater scale.

TypeDirect peer
Description

UK-based integrated drug discovery CRO offering medicinal chemistry, in vitro biology, DMPK and computational chemistry. Most direct comparable in size, geography and service mix to BioAscent, competing for similar biotech and mid-pharma integrated discovery contracts.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers13 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BioAscent

Drug Discovery Contract Research Servicesbioascent.com

BioAscent firmographics

Firmographics
Name
BioAscent
Legal name
BioAscent Discovery Ltd
Website
https://bioascent.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
51–100 employees
Ownership category
akta.pro rank

BioAscent industry classification

Industry
Product category
Drug Discovery Contract Research Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)

Keywords

  • Drug discovery services
  • Compound management
  • Contract research organization
  • Medicinal chemistry
  • High-throughput screening

Where BioAscent is headquartered

Location

Headquarters

HQ city
Newhouse
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

BioAscent business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Integrated Drug Discovery Services: Full-service CRO offering integrated drug discovery projects covering assay development, screening, medicinal chemistry, synthetic chemistry, computational chemistry, and DMPK services. Provides both standalone and fully integrated project delivery.
  2. Compound Management Services: Compound aggregation, storage, weighing, dissolution, plating (including acoustic dispensing), LC-MS analysis, and distribution services. Operating since 2005 with €20 million facility. Cost-effective, transparent activity-based pricing model.
  3. Custom Library Sourcing: Rapid selection and sourcing of custom libraries through established partnerships with compound suppliers and aggregators such as MolPort.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goActivity-based pricing for compound management services
Professional services/ project-basedMulti-year contractIntegrated drug discovery project pricing

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

BioAscent product offering

Product offering

Core offering

BioAscent is a contract research organization (CRO) providing science-led integrated drug discovery services, including de novo assay development, medicinal and synthetic chemistry, computational chemistry, in vitro biosciences, DMPK, and access to in-house diversity and fragment libraries. It also offers parallel compound management services covering sourcing, secure storage, cherry-picking, plating, and global shipping of chemical libraries, supported by a proprietary web-based inventory platform (Compound Connect) for CRO network coordination.

Product overview

BioAscent offers integrated drug discovery services as a unified platform combining multiple specialized capabilities. The core Integrated Drug Discovery Services platform encompasses Discovery Biology (biochemical/biophysical/cellular assays), In Silico Discovery (computational chemistry and AI), Medicinal Chemistry, Protein Science and Structural Biology, and access to proprietary compound libraries (diversity, fragment, and chemogenomic). Compound Management operates as a parallel core service line providing secure compound storage, cherry picking, plating, and logistics via the proprietary Compound Connect web platform. The services are designed to work together seamlessly on a single site, enabling rapid turnaround from synthesis to screening data for customers ranging from virtual biotechs to big pharma.

Differentiator

Problem solved

Functional benefit

Products and services

  • Integrated Drug Discovery Services Comprehensive integrated drug discovery offering combining de novo assay development, target analysis, bespoke screening strategies, compound screening (including HTS), medicinal and synthetic chemistry, computational chemistry, DMPK, and in-house diversity and fragment libraries for biotech, pharma, and academic customers.
  • Compound Management Big-pharma calibre compound management services including rapid compound sourcing, secure storage, flexible cherry picking, plating (including acoustic dispensing), LC-MS analysis, and global shipping and logistics, supported by a proprietary web-based inventory platform (Compound Connect).
  • Compound Connect Proprietary web-based inventory and ordering system providing secure customer access to a customized online compound library, with a fully auditable order fulfilment system interfacing with Titian Mosaic compound management software.
  • Medicinal Chemistry Services Proven medicinal and synthetic chemistry expertise supporting drug design, hit-to-lead and lead optimisation campaigns for external pharma and biotech customers.
  • In Silico Discovery and Data Analysis Computational chemistry and AI-driven drug discovery services including virtual screening, library design, cheminformatics, molecular dynamics simulations, and generative chemistry for accelerated compound design.
  • Discovery Biology Services Biochemical, biophysical, and cellular assay development with screening expertise across target classes including GPCRs, kinases, ion channels, and mitochondrial targets.
  • Protein Science and Structural Biology Protein production, Surface Plasmon Resonance (SPR) biophysics, and structural biology services including X-ray crystallography and NMR for target-ligand interaction characterisation.
  • In-house Diversity, Fragment and Chemogenomic Libraries Proprietary compound libraries including diversity, fragment, and chemogenomic collections for high-throughput screening campaigns.
  • Screening and Characterization Services High-throughput screening (HTS) capabilities including functional screening, cell-based phenotypic screening, and whole-organism screening for hit identification.
  • Physicochemical Profiling and DMPK Drug metabolism and pharmacokinetics (DMPK) profiling including physicochemical property characterisation and ADMETox prediction services.

Quantifiable outcome

  • 81% compound annualised growth over two years
  • +5 more outcomes

Companies that use BioAscent

Customer profile

Named customers13 records

Segments4 records

Ideal customer profiles4 records

BioAscent technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature6 records

BioAscent partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core and minor.

  • University of GlasgowcoreStrategic or Co-development Partner · 30 March 2026Successful collaboration on GPR84 antagonist programme with publication of results. Collaboration between BioAscent researchers and University of Glasgow on GPR84 antagonist drug discovery programme.
  • Magnitude BiosciencesminorStrategic or Co-development Partner · 26 February 2026Research collaboration to profile Chemogenomics Library using VivoScan™ whole-organism screening platform, combining Magnitude's expertise in whole-organism screening with BioAscent's compound management capabilities.
  • University of GlasgowcoreStrategic or Co-development Partner · 19 November 2025Partnership to fund two PhD studentships supported by Medical Research Scotland, focusing on cancer and metabolic disease research. Project aims to develop new therapeutic approaches for energy metabolism in cancer and predictive models for insulin resistance, leveraging BioAscent's drug discovery capabilities.
  • Keltic Pharma TherapeuticscoreTechnology or Integration · 19 November 2025Strategic collaboration to expand peptide discovery capabilities for GPCR targets. Partnership involves integration of Keltic's PEPSMOL© platform into BioAscent's drug discovery services, aiming to accelerate drug development across multiple therapeutic areas.
  • ExscientiacoreStrategic or Co-development Partner · 19 June 2023Collaboration on high-throughput screen (HTS) to identify novel allosteric compounds targeting HSD17β13 enzyme. BioAscent provided assay development and screening services; co-publication on Particle Swarm Optimisation technique published in Cell Press Patterns.
  • European Lead Factory Consortium (AstraZeneca, Bayer, Grunenthal, Janssen, Merck KgaA, Sanofi, Servier, UCB)coreStrategic or Co-development PartnerCompound management services for European Lead Factory collections from major pharmaceutical partners including AstraZeneca, Bayer, Grunenthal, Janssen, Merck KgaA, Sanofi, Servier, and UCB.
  • University of LincolnminorStrategic or Co-development PartnerAcademic collaboration with postdoctoral researcher Joan Clark-Nicolas on AI-driven design of novel GLP-1R PAMs using REINVENT4 deep generative reinforcement learning framework.
  • University of EdinburghminorStrategic or Co-development PartnerAcademic collaboration with PhD student Ryan Zhu on generative AI for NLRP3 inflammasome inhibitor design using REINVENT4 framework.
  • University of StirlingminorStrategic or Co-development PartnerSummer internship collaboration with MSc student Donaldson Chuks Okolo on applying machine learning to predict buffer effects on assay performance using Bayesian optimisation.
  • Apollo TherapeuticsminorStrategic or Co-development PartnerCollaboration on screening and characterisation of mitochondria gatekeeper protein inhibitors using Seahorse XF Pro Platform.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

BioAscent competitors and assessment

Company assessment

Broad incumbents

  • WuXi AppTec: China-headquartered global CRO/CDMO with end-to-end small molecule discovery, biology and DMPK capabilities. Sets the global price/throughput benchmark for integrated discovery work that BioAscent competes against for biotech and pharma R&D budgets.
  • Pharmaron: China-founded, globally integrated CRO/CDMO with chemistry, biology, DMPK and safety services. Competes for the same pharma/biotech integrated discovery contracts, particularly on price-sensitive programmes where scale matters.
  • Charles River Laboratories: Global CRO with substantial early-stage discovery, safety assessment and manufacturing services. Competes with BioAscent in integrated discovery and adjacent services, but at far greater scale and across a much broader portfolio.
  • Evotec: Large Hamburg-based drug discovery CRO with end-to-end platforms across modalities including small molecules, biologics and cell therapy. Comparable integrated discovery offering but at much greater scale and broader modality coverage than BioAscent.
  • Eurofins Discovery: Discovery arm of Eurofins Scientific offering in vitro pharmacology, ADME and integrated discovery services. Overlaps with BioAscent's biology and DMPK capabilities and competes for European biotech outsourcing budgets at greater scale.

Direct peers

  • HitGen: China-based DNA-encoded library and small molecule discovery CRO. Highly comparable in screening library and early discovery specialisation, and increasingly competes for biotech customers seeking library-driven hit identification services globally.
  • Domainex: UK-based integrated drug discovery CRO with medicinal chemistry, biology and DMPK services. Closely comparable in scale and service offering, competing head-to-head with BioAscent for UK and European biotech discovery outsourcing.
  • Concept Life Sciences: UK-headquartered CRO (formed from Peakdale Molecular and other acquisitions) offering chemistry, biology and DMPK services. Comparable UK-based discovery CRO with overlapping customer base in European biotech and pharma.
  • Sygnature Discovery: UK-based integrated drug discovery CRO offering medicinal chemistry, in vitro biology, DMPK and computational chemistry. Most direct comparable in size, geography and service mix to BioAscent, competing for similar biotech and mid-pharma integrated discovery contracts.

Regional players

  • Selvita: Poland-based integrated drug discovery CRO with medicinal chemistry, in vitro biology and DMPK. Comparable in service mix and emerging-stage positioning; competes mainly in Central/Eastern Europe rather than the UK-centric footprint of BioAscent.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

BioAscent social profiles

Digital presence

BioAscent financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BioAscent leadership team

Management profile

Number of profiles

Profiles11 records

BioAscent funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BioAscent M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioAscent

What does BioAscent do?

BioAscent is a contract research organization (CRO) providing science-led integrated drug discovery services, including de novo assay development, medicinal and synthetic chemistry, computational chemistry, in vitro biosciences, DMPK, and access to in-house diversity and fragment libraries. It also offers parallel compound management services covering sourcing, secure storage, cherry-picking, plating, and global shipping of chemical libraries, supported by a proprietary web-based inventory platform (Compound Connect) for CRO network coordination.

Is BioAscent a public or private company?

BioAscent is a private company. It is classified as venture growth investor backed and is currently operating.

When was BioAscent founded?

BioAscent was founded in 2013. It employs 51 to 100 people.

Where is BioAscent based?

BioAscent is headquartered in Newhouse, United Kingdom, in the Europe region.

How does BioAscent make money?

Three revenue lines are on record. Integrated Drug Discovery Services are the primary driver. The others are compound Management Services and custom Library Sourcing.

Who are BioAscent's main competitors?

Broad incumbents on record are WuXi AppTec, Pharmaron, Charles River Laboratories, Evotec and Eurofins Discovery. Direct peers are HitGen, Domainex, Concept Life Sciences and Sygnature Discovery. Selvita is listed as a regional player.

Does BioAscent have an API?

No public API is recorded for BioAscent.

What industry is BioAscent in?

BioAscent's product category is Drug Discovery Contract Research Services. Its primary akta.pro industry code is HLAGAAAB, Preclinical CROs (Discovery/Pharmacology/DMPK), with a secondary code of HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PharmiWeb.comBioAscent and the University of Glasgow secure prestigious PhD studentships from Medical Research ScotlandBioAscent and the University of Glasgow have been awarded two PhD studentships funded by Medical Research Scotland to advance research in cancer and metabolic diseases. The first studentship will support research on targeting energy metabolism in cancer under Professor Kostas Tokatlidis, while the second will focus on developing predictive models for insulin resistance under Dr. Brian Hudson. The partnership aims to provide industrial training to early-career scientists while strengthening Scotland's position as a hub for scientific innovation in drug discovery.GlasgowriversideinnovationdistrictKeltic Pharma secure $1.3M from Gates Foundation to tackle malariaKeltic Pharma Therapeutics, a University of Glasgow spin-out, has been awarded $1.3 million (£1.15 million) in funding from the Bill and Melinda Gates Foundation to accelerate its malaria drug discovery programme targeting IND enablement within 12 months. The funding supports development of a single-dose malaria cure addressing a disease that causes over 600,000 deaths annually with children under five most vulnerable and treatment resistance rising. The company has also announced a separate partnership with Scotland-based BioAscent to provide biotech and pharma customers access to its PEPSMOL® peptide discovery platform for GPCR targets.GlasgowcityofscienceandinnovationKeltic Pharma Secures $1.3m Gates Foundation Funding to Advance Single-Dose Malaria CureKeltic Pharma Therapeutics secured $1.3 million in funding from the Bill and Melinda Gates Foundation to accelerate its malaria drug discovery programme aimed at developing a single-dose cure for malaria. The funding will support IND-enabling studies as the company works toward clinical development of the treatment, which targets a disease causing over 600,000 deaths annually with rising treatment resistance. The company, a University of Glasgow spin-out founded in 2019, is simultaneously expanding through a collaboration with Scotland-based BioAscent for peptide discovery services.PharmiWeb.comBioAscent and Keltic Pharma Therapeutics partner to give customers access to cutting-edge peptide discovery platform for GPCR targetsBioAscent, a provider of integrated drug discovery services based in Glasgow, has announced a strategic collaboration with Keltic Pharma Therapeutics to give BioAscent customers access to Keltic’s proprietary PEPSMOL© platform. The platform enables translation of cyclic peptide hits into potent, selective small molecules, specifically targeting G-protein coupled receptors (GPCRs) which have historically been difficult to address with conventional methods. The partnership combines BioAscent’s screening and medicinal chemistry expertise with Keltic’s peptide-to-small-molecule approach to accelerate drug discovery for challenging targets.